Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Complementation Tests00:49

Complementation Tests

4.9K
A complementation test is a simple cross to identify whether the two mutations are located on the same gene or different genes. It was first performed by Edward Lewis in the 1940s while working on fruit flies. He developed the test to identify the location and arrangement of different mutations on chromosomes.
Organisms heterozygous for different mutations are crossed pairwise in all combinations. If present on different genes, the mutations can complement each other by providing the missing...
4.9K
Humoral Immune Responses01:36

Humoral Immune Responses

72.4K
Overview
72.4K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Nanobodies against Plasmodium adhesins that block receptor engagement and malaria parasite invasion.

The Biochemical journal·2026
Same author

Inflammatory Stewardship-A Perspective for Active Management of Acute Inflammation.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2026
Same author

Monoclonal nephritic factors reveal insights into C3 convertase dynamics and dysregulation.

bioRxiv : the preprint server for biology·2026
Same author

In vivo evidence of effective complement modulation by TriFu in comparison to C5 inhibition and complement depletion.

Blood advances·2026
Same author

Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti-C5 therapy.

HemaSphere·2026
Same author

Autoantibodies to IL-1Ra and PGRN in severe COVID-19 are associated with inflammation-induced hyperphosphorylated antigen isoforms.

Nature communications·2026

相关实验视频

Updated: Jun 18, 2025

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

30.6K

补充模型疾病是阴性夜间血红蛋白尿症.

Christoph Q Schmidt1, Britta Höchsmann2,3, Hubert Schrezenmeier2,3

  • 1Institute of Experimental and Clinical Pharmacology, Toxicology and Pharmacology of Natural Products, University of Ulm Medical Centre, Ulm, Germany.

European journal of immunology
|August 5, 2024
PubMed
概括

透性夜间血红素尿 (PNH) 治疗面临突破性血液溶解的挑战. 新的补充抑制剂旨在克服这些局限性,以获得更好的患者结果.

关键词:
补充系统的补充系统.补充疗法是一种补充疗法.丹尼科邦丹尼科邦在Eculizumab中使用.这是Iptacoplan的计划.在PNH中,PNH是指PNH.帕洛克斯夜性血红素尿.在Pegcetacoplan上使用Pegceta.拉夫鲁兹马布的使用情况

更多相关视频

Measuring the 50% Haemolytic Complement CH50 Activity of Serum
08:26

Measuring the 50% Haemolytic Complement CH50 Activity of Serum

Published on: March 29, 2010

37.8K
Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry
07:20

Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry

Published on: May 19, 2020

7.2K

相关实验视频

Last Updated: Jun 18, 2025

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

30.6K
Measuring the 50% Haemolytic Complement CH50 Activity of Serum
08:26

Measuring the 50% Haemolytic Complement CH50 Activity of Serum

Published on: March 29, 2010

37.8K
Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry
07:20

Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry

Published on: May 19, 2020

7.2K

科学领域:

  • 血液学 血液学 血液学
  • 免疫学 免疫学 免疫学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 阴性夜间血红蛋白尿 (PNH) 是一种罕见的,严重的血液学疾病.
  • 它的特征是补充介导的血管内血解,导致贫血和血栓形成.
  • 第一个向C5的补充抑制剂eculizumab于2007年获得批准.

研究的目的:

  • 审查PNH中的补充激活和抑制.
  • 讨论对C5抑制剂的低最佳反应.
  • 探索用于PNH的新型补充疗法.

主要方法:

  • 在PNH中对补剂抑制的初始,当前和未来方面进行审查.
  • 对C5抑制剂的亚最佳反应的四个原因的识别和机制剖析.
  • 讨论针对近接级联蛋白的新兴补充疗法.

主要成果:

  • 埃奎利祖马布稳定了血液学参数,并减少了PNH中血栓事件.
  • 低于最佳的反应与药理动力学/药理动力学突破性血液溶解,残留血管内血液溶解和血管外血液溶解有关.
  • 多重补充抑制剂已被批准或在临床试验中用于PNH.

结论:

  • 尽管C5抑制剂成功,但在PNH中仍然存在残留血液溶解和血管外血液溶解.
  • 针对近位通路的新型补充抑制剂正在开发中,以解决这些问题.
  • PNH研究非常活跃,正在调查各种补充抑制剂的意外突破事件.